Back to results
US 11,590,123 B2Granted
Ophthalmic compositions
AssigneeAerie Pharmaceuticals, Inc.
InventorsCheng-Wen Lin, Casey Kopczynski, Mitchell A. deLong, Jill M. Sturdivant, Ramesh Krishnamoorthy
Life of this patent
Estimating the term…
Abstract
The present disclosure provides an ophthalmic composition comprising 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts; about 0.01% weight/volume to about 1.0% weight/volume of a buffer; and about 0.01% weight/volume to about 10% weight/volume of a tonicity agent.
Claims16
An ophthalmic formulation, consisting of:
- 0.0285 weight/volume % of a dimesylate salt of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate;
- 0.05 weight/volume % of boric acid;
- 4.7 weight/volume % of mannitol;
- water;
- and
- a pH of 5.
3 more elements
A method of treating glaucoma in a subject in need thereof, comprising topically administering to an eye of the subject an ophthalmic formulation consisting of:
- 0.0285 weight/volume % of a dimesylate salt of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate,
- 0.05 weight/volume % of boric acid,
- 4.7 weight/volume % of mannitol,
- water, and
- a pH of 5.
2 more elements
Dependencies are inferred from the claim text.